NEW YORK, Sept. 20 /PRNewswire/ -- NeoStem, Inc. (NYSE Amex: NBS) ("NeoStem" or the "Company"), an international biopharmaceutical company with operations in the U.S. and China, announced today that its CEO, Dr. Robin Smith, is appearing on WALLSTREETCAST, a national weekly television program airing on the FOX Business Network.
The show's first segment was aired on Saturday, September 18th, and additional segments will air each upcoming Saturday at 1:30 p.m. Eastern Time through October 9th. They may also be found online at http://www.moneychannel.tv.
Dr. Smith's appearances are part of a media agreement with the Money Channel Inc. that allows the Company to tell its story to a broader audience through interviews airing each week on "Steve Crowley's American Scene," a 20-year on-air financial national radio show, and WALLSTREETCAST, which airs on the FOX Business Network during certain times of the year. Both programs feature personal finance advice, stock market-related news and advice, and include regular CEO interviews of micro-cap and small-cap companies. American Scene alone has over 3,000,000 listeners on the three-hour daily radio broadcasts and airs on hundreds of radio channels nationwide through the IRN/USA Radio Network affiliates.
"This is a great opportunity to reach out to our valued shareholders to share with them milestones we are targeting in our Company's development as we continue to work towards growing shareholder value," said Dr. Smith.
About Money Channel Inc.
The Money Channel Inc., headquartered in Coconut Creek, Florida, has operated as a media company since 2004. Its CEO, Stephen Crowley, is a former Price Waterhouse and Co. CPA-Manager, the former Money Editor of ABC's Good Morning America as well as the author of Money for Life, published by Simon & Schuster Inc. Mr. Crowley and his team have produced more than 9,000 national radio and television programs since 1982 in markets ranging from New York to San Diego and from Seattle to Miami. American Scene Radio is also co-branded with Investors Business Daily at www.investors.com/americanscene and with www.TheStreet.com founded by Jim Cramer.
About NeoStem, Inc.
NeoStem, Inc. is engaged in the development of stem cell-based therapies, pursuit of anti-aging initiatives and building of a network of adult stem cell collection centers in the U.S. and China that are focused on enabling people to donate and store their own (autologous) stem cells for their personal use in times of future medical need. The Company is also the licensee of various stem cell technologies, including a worldwide exclusive license to VSEL™ Technology which uses very small embryonic-like stem cells, shown to have several physical characteristics that are generally found in embryonic stem cells, and is pursuing the licensing of other technologies for therapeutic use. NeoStem's majority-controlled Chinese pharmaceutical operation, Suzhou Erye, manufactures and distributes generic antibiotics in China. For more information, please visit: http://www.neostem.com .
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include the future of VSEL™ Technology and adult stem cells as a viable treatment option, about which no assurances can be given. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission as well as other periodic filings made with the Securities and Exchange Commission. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.For more information, please contact:NeoStem, Inc.Robin Smith, CEOPhone: +1-212-584-4174Email: email@example.com Web: http://www.neostem.com
|SOURCE NeoStem, Inc.|
Copyright©2010 PR Newswire.
All rights reserved